In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

[1]  K. Verbeke,et al.  A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. , 2011, Biomedical chromatography : BMC.

[2]  K. Verbeke,et al.  In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine‐Treated as Compared With Tacrolimus‐Treated Renal Allograft Recipients , 2011, Clinical pharmacology and therapeutics.

[3]  A. Israni,et al.  Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium , 2011, Transplantation.

[4]  N. Kamar,et al.  Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies , 2010, Transplantation.

[5]  K. Verbeke,et al.  Tacrolimus Dose Requirements and CYP3A5 Genotype and the Development of Calcineurin Inhibitor-Associated Nephrotoxicity in Renal Allograft Recipients , 2010, Therapeutic drug monitoring.

[6]  D. Cooper,et al.  Multi-center evaluation of a commercial Kit for tacrolimus determination by LC/MS/MS. , 2010, Clinical biochemistry.

[7]  M. Loriot,et al.  Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing , 2010, Clinical pharmacology and therapeutics.

[8]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part II , 2010, Clinical pharmacokinetics.

[9]  L. Rostaing,et al.  A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  Leslie Z Benet,et al.  The drug transporter-metabolism alliance: uncovering and defining the interplay. , 2009, Molecular pharmaceutics.

[11]  D. Kuypers,et al.  New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation , 2009, Therapeutic drug monitoring.

[12]  M. Radovich,et al.  Association of genotypes of the CYP3A cluster with midazolam disposition in vivo , 2009, The Pharmacogenomics Journal.

[13]  V. Haufroid,et al.  Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.

[14]  B. Bammens,et al.  Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). , 2008, Nephrology, Dialysis and Transplantation.

[15]  J. D. de Fijter,et al.  CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients , 2008, Pharmacogenetics and genomics.

[16]  E. Lerut,et al.  CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients , 2007, Clinical pharmacology and therapeutics.

[17]  E. Kharasch,et al.  Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam , 2007, Clinical pharmacology and therapeutics.

[18]  H. Schwilden,et al.  Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation , 2007, European Journal of Clinical Pharmacology.

[19]  Edward Cole,et al.  Therapeutic monitoring of calcineurin inhibitors for the nephrologist. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[20]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[21]  M. Hebert,et al.  EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO , 2006, Drug Metabolism and Disposition.

[22]  J. Trotter,et al.  Immunosuppression: Evolution in Practice and Trends, 1994–2004 , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  S. Bates,et al.  Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients , 2005, Clinical Cancer Research.

[24]  Michael Oellerich,et al.  Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. , 2005, Clinical chemistry.

[25]  D. Greenblatt,et al.  Genotype‐phenotype Associations of Cytochrome P450 3A4 and 3A5 Polymorphism with Midazolam Clearance in Vivo , 2005, Clinical pharmacology and therapeutics.

[26]  R. Harrington.  Part II , 2004, Bitter Freedom.

[27]  T. Habuchi,et al.  Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.

[28]  D. Oh,et al.  Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states , 2004, Clinical pharmacology and therapeutics.

[29]  S. Masuda,et al.  CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. , 2004, Pharmacogenetics.

[30]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.

[31]  P. Syrris,et al.  The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  A. Telenti,et al.  Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects , 2004, European Journal of Clinical Pharmacology.

[33]  U. Christians,et al.  CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam , 2004, Journal of Pharmacology and Experimental Therapeutics.

[34]  R. Kim,et al.  Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. , 2003, Pharmacogenetics.

[35]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[36]  P. Syrris,et al.  Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement , 2002, Transplantation.

[37]  Jin‐ding Huang,et al.  Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[38]  D. Shen,et al.  Can oral midazolam predict oral cyclosporine disposition? , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  D. Greenblatt,et al.  Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.

[40]  N. Undre,et al.  The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[41]  J. Gorski,et al.  The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.

[42]  Louise Poissant.  Part I , 1996, Leonardo.

[43]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[44]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[45]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[46]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[47]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[48]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.

[49]  D. Kuypers,et al.  Pharmacogenetics in solid organ transplantation: current status and future directions. , 2008, Transplantation reviews.

[50]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[51]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.